Karolina Okła - Gynecology

Author Information

Karolina Okła is affiliated with The First Department of Gynecologic Oncology and Gynecology at the Medical University of Lublin, located in Lublin, Poland. Her research primarily focuses on gynecologic oncology, with a significant contribution to the understanding and treatment of various cancers.

Research Contributions

Karolina Okła has made substantial contributions to the field of gynecologic oncology and cancer research. Her work includes exploring the role of tissue-resident memory T cells in tumor immunity and immunotherapy, investigating the impact of Lycium barbarum (goji berry) on human breast cancer and its antioxidant profile, and examining the accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in ovarian cancer patients. Additionally, she has studied the pharmacological interactions between chemotherapy drugs and other therapeutic agents in various cancer cell lines.

Aliases

Karolina Okła is also known by the following aliases:

K Okła K Okla Karolina Okla

Publication and Citation Metrics

Metric	Value
Total Papers	35
Total Citations	844
h-index	13

Publications:

Tissue-resident memory T cells in tumor immunity and immunotherapy

DOI: 10.1084/jem.20201605

Year: 2021

Lycium barbarum (goji berry), human breast cancer, and antioxidant profile

DOI: 10.1016/B978-0-12-819547-5.00035-3

Year: 2021

Contributors

DOI: 10.1016/b978-0-12-819547-5.09988-0

Year: 2021

Correction to: Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1

DOI: 10.1186/s12967-020-02431-8

Year: 2020

Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1

DOI: 10.1186/s12967-020-02389-7

Year: 2020

Cancer SLC43A2 alters T cell methionine metabolism and histone methylation

DOI: 10.1038/s41586-020-2682-1

Year: 2020

Gemcitabine and Selected mTOR Inhibitors in Uterine Sarcomas and Carcinosarcoma Cells- an Isobolographic Analysis

DOI: 10.7150/ijms.48187

Year: 2020

Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity—An Isobolographic Analysis

DOI: 10.3390/ijms20153663

Year: 2019

Fucoidan Structure and Activity in Relation to Anti-Cancer Mechanisms

DOI: 10.3390/md17010032

Year: 2019

P63 Targeted therapies in uterine sarcomas and carcinosarcomas- the summary of ENITEC (european network for individualised treatment of endometrial cancer) collaboration project

DOI: 10.1136/ijgc-2019-ESGO.125

Year: 2019

What is hCG?

When is Postnatal Surgery Necessary?

Are There Risks Associated with Excessive Intake?

What are congenital uterine abnormalities?

How Does Carbohydrate Loading Help?

What Are Gynecology Certifications?

What role does diet play in hormonal balance?

How Do Psychological Barriers Come Into Play?

What are the Common Molecular Tests Used in Gynecology?

How Can Regret Be Addressed Post-Decision?

Partnered Content Networks

Relevant Topics